Saturday, September 5, 2026
ExploreSearch
Via News
Via News Knowledge File

Sanofi

organization80% conf.·synced Aug 19, 2026

Pharmaceutical company partnered with Teva for duvakitug additional indications

22
sourced metrics
805
relationships
20
stated objectives
8
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Market Cap
54837636507USD
Aug 18, 2026reference only
Stock Return Ytd
-6.8%
Aug 18, 2026reference only
Stock Price
44.97USD
Aug 18, 2026reference only
Price 52 Week Low
41.33USD
Aug 18, 2026reference only
Price 52 Week High
52.34USD
Aug 18, 2026reference only
Margin
-68.7percent
Apr 1, 2026source
Eps
4.97USD
Mar 3, 2026⚠ sources conflictsource
Rare Disease Experience
40years
Feb 2, 2026source
Rare Disease Commitment
40years
Feb 2, 2026source
Collaboration Revenue
5.9billion_USD
Jan 30, 2026⚠ sources conflictsource
Cash
877000000.0USD
Dec 31, 2025reference only
Total Assets
126805000000.0USD
Dec 31, 2025reference only
Gross Profit
33667000000.0USD
Dec 31, 2025reference only
Rd Expense
7842000000.0USD
Dec 31, 2025reference only
Shares Outstanding
1219427096.0shares
Dec 31, 2025reference only
Acquisition Price Per Share
15.50USD
Dec 24, 2025source
China Approvals 2025
5approvals
Dec 11, 2025source
China Drug Approvals 2025
5approvals
Dec 11, 2025source

Stated objectives

Advance Dynavax's shingles vaccine candidate (Z-1018) through clinical development

source
stated

Augment Sanofi's presence in adult immunization by combining Dynavax's vaccines with Sanofi's global scale, development capabilities and commercial reach

source
stated

Provide vaccine protection across the lifespan through differentiated vaccine portfolio

source
stated

Submit global regulatory submissions for amlitelimab

source
stated

Report results from AQUA and ESTUARY phase 3 studies

source
stated

Study dupilumab in chronic pruritus of unknown origin, lichen simplex chronicus, and allergic fungal rhinosinusitis in phase 3 studies

source
stated

Complete global regulatory submissions for amlitelimab

source
stated

Publish results from AQUA and ESTUARY phase 3 studies

source
stated

Present COAST 1, COAST 2, SHORE and ATLANTIS results at upcoming medical conferences

source
stated

Study dupilumab in phase 3 trials for chronic pruritus of unknown origin, chronic lichen simplex, and allergic fungal rhinosinusitis

source
stated

Relationship graph · 805 connections

Employs
237
Developed by
141
regulates
88
Competes with
72
headquartered in
61
regulated by
19
researched at
18
Owns
16
headquartered in
Paris

Via News coverage

Jade Biosciences Targets 2027 Phase 1 Trial as Global Autoimmune Drug Race Intensifies
February 18, 2026
GSK's Six-Monthly Asthma Biologic Could Reshape Treatment Standards From London to Lagos
February 18, 2026
Canopy Growth And Technical Communications Corporation On The List Of Winners And Losers Of Wednesday's US Session
March 27, 2024
Canaan And Signet Jewelers Limited On The List Of Winners And Losers Of Wednesday's US Session
March 20, 2024
Teva Pharmaceutical Already 4% Up, Almost One Hour Before The Market Open
February 26, 2024
Sangamo Therapeutics And FibroGen On The List Of Winners And Losers Of Tuesday's US Session
February 20, 2024
Agenus And Fastly On The List Of Winners And Losers Of Thursday's US Session
February 15, 2024
Artificial Intelligence Predicts Next Session's Price Change For RenaissanceRe Hold, Honda, HCA Holdings
February 8, 2024
This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Funding Surge: Capital Floods Fintech, Foundation Models, and Autonomous Systems
A concentrated burst of AI-linked funding on 2026-08-28 pushed well over $1.5B into companies spanning fraud/identity fintech (Socure, which also acquired Fravity), foundation models (Stability AI), AI agents and enterprise tooling (Instinct, Generalist AI, Emerald AI, Owner), and AI-adjacent autonomous/aerospace ventures (Gatik, Regent Craft). The breadth and simultaneity of these rounds signal that investor appetite for AI is not concentrated in a single vertical but is broadening into applied and infrastructure-adjacent domains, with consolidation (Socure-Fravity) beginning alongside fresh capital formation.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,269 source documents archived
Query this data → isubstrate.com